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MxA is an interferon-induced dynamin-like GTPase
with wide-ranging antiviral activity, which hinges
upon detection of unique viral structures that differ
across virus families. Despite elucidation of its struc-
ture, the basis of MxA antiviral specificity remains
enigmatic. We used an evolution-guided approach
to identify the loop L4 of MxA as a hotspot for
recurrent positive selection in primates. Further, we
show that single amino acid changes in L4 are neces-
sary and sufficient to explain dramatic differences
in species-specific antiviral activity of primate MxA
proteins against the orthomyxoviruses Thogoto virus
and influenza A virus. Taken together, our findings
identify a genetic determinant of MxA target recogni-
tion and suggest a model by which MxA achieves
antiviral breadth without compromising viral spe-
cificity.
INTRODUCTION
MxA is a dynamin-like GTPase with antiviral activity against a
wide range of RNA and DNA viruses (Haller and Kochs, 2011).
The antiviral breadth exhibited by MxA is remarkable because
it hinges upon detection of unique viral structures that differ
across virus families. For example, differences in resistance
and susceptibility between avian (MxA-sensitive) and human
(MxA-resistant) influenza virus isolates have been shown to be
solely dependent on differences in the nucleoprotein (NP) (Zim-
mermann et al., 2011). Furthermore, MxA activity against the
alphavirus Semliki Forest virus (SFV) is independent of SFV NP
or other structural proteins (Landis et al., 1998), andMxA antiviral
activity against DNA viruses like hepatitis B virus (HBV) (Li et al.,
2012) and African swine fever virus (ASFV) (Netherton et al.,
2009) is dependent on unique viral components. However, the
evolutionary and molecular basis for MxA antiviral specificity is
unknown.598 Cell Host & Microbe 12, 598–604, October 18, 2012 ª2012 ElsevThe recently solved crystal structure of human MxA (hsMxA)
highlights the difficulty in pinpointing molecular determinants
of MxA antiviral specificity. The MxA structure resembles that
of other members of the dynamin-like large GTPase superfamily
(Gao et al., 2011), consisting of a N-terminal GTPase domain (G
domain) and a C-terminal stalk. These two structural domains
are linked by a bundle-signaling element (BSE) that is necessary
to transfer structural changes during GTP binding and hydrolysis
to the stalk structure. Nonetheless, while the crystal structure of
MxA illustrated the coupling between different domains, it did
not reveal a molecular basis for the long-standing problem of
MxA antiviral specificity.
In order to determine the basis of MxA specificity for viral
recognition, we took an evolution-guided functional approach
that capitalizes on the antagonistic arms race between MxA
and its viral targets, and the genomic signatures it leaves on
host genomes. The rapid accumulation of amino acid replace-
ment changes (dN) relative to synonymous changes (dS), or
positive selection (dN/dS > 1), is one hallmark of antagonistic
evolution between host and viral genomes. Because positive
selection underlies phenotypic adaptation at antiviral inter-
faces (Daugherty and Malik, 2012; Sawyer et al., 2005), we pre-
dict that the hypothetical viral substrate interface(s) of MxA
would have evolved with the strongest signature of positive
selection.
Here we show that the surface-exposed loop L4, which
protrudes from the compact structure of the MxA stalk, bears
such a signature of recurrent positive selection. We demonstrate
that genetic variation in L4 of primateMxA is amajor determinant
of its species-specific antiviral activity against the orthomyxovi-
ruses Thogoto virus (THOV) and an avian influenza A virus, and
a single positively selected amino acid in L4 is sufficient to alter
the antiviral specificity of primate MxA. Moreover, we show that
hsMxA L4 can function as a modular determinant of antiviral
specificity in the context of the highly divergent mouse ortholog
to confer antiviral protection. We propose that, while the archi-
tecture of Mx proteins has been evolutionarily conserved, the
antiviral specificity determinants have been subject to recurrent
arms races with viral substrates. Taken together, our findings
identify L4 as a genetic determinant of MxA antiviral specificity,ier Inc.
Figure 1. Evolution of Primate MxA
(A) The phylogeny was built using orthologous MxA sequences from 24 primate species (Figure S1 and Table S1), which is congruent with a previously published
primate phylogeny (Perelman et al., 2011).
(B) The loop L4 (amino acids 533-572) protein sequence alignment is shown from representative primates (top). Specific codons found to be evolving under
positive selection in primate MxA are indicated in a linear schematic (middle) or a model of the MxA crystal structure (bottom) (Gao et al., 2011), where sites with
a posterior probability greater than 0.95 and 0.99 are highlighted in orange and red, respectively. In the linear structure ‘‘B’’ depicts the three parts of MxA that
form the bundle-signaling element (BSE).
(C) Evolutionary analysis for positive selection in primateMxA. P values generated frommaximum likelihood ratio tests that fit the data tomodels of neutral (M7) or
adaptive (M8) evolution are given for the entire MxA coding sequence (including or excluding new world monkey (NWM) sequences) or specific domains of the
protein as indicated. i. Percentage of codons evolving under positive selection (p1). ii. Associated average dN/dS (u) of p1 sites. iii. Codons with a high posterior
probability (PP > 0.90) that supports the likelihood of a site having a dN/dS > 1 are presented with the PP for each residue in parentheses. Amino acids refer to
residues found at indicated positions in hsMxA. iv. Indels removed from alignment. v. StalkDL4 refers to an analysis of the stalk with amino acids 533-572
removed.
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eate host-virus interactions.
RESULTS
Rapid Evolution of the Unstructured Loop L4 in
Primate MxA
To evaluate how the antiviral specificity of MxA has been shaped
during the evolution of primates, we amplified, sequenced and
alignedMxA coding regions from 24 primate species represent-
ing43 million years of evolutionary divergence (Figures 1A and
S1 and Table S1). A phylogenetic tree generated from theseMxACell Hostsequences was congruent with a previously published primate
phylogeny (Perelman et al., 2011) confirming that the MxA
sequences obtained were orthologous (Figure 1A). Using this
data set, we calculated an average dN/dS value of 0.32 for
MxA, which is consistent with purifying selection having acted
on the majority of the MxA gene over primate evolution.
However, an average dN/dS signature can obscure recurrent
positive selection that might have acted on particular codons
or protein domains. Indeed, when we compared maximum likeli-
hood codon-based models that disallow positive selection
(model M7) to those that allow dN/dS to exceed 1 (model M8),
we found strong evidence that MxA has recurrently evolved& Microbe 12, 598–604, October 18, 2012 ª2012 Elsevier Inc. 599
Figure 2. Species-Specific Antiviral Activity
Results from Sequence Divergence in Loop
L4 of Primate MxA
(A) THOV minireplicon activity (luciferase levels)
was measured 24h post-transfection, and was re-
ported relative to levels observed in the absence of
MxA. hsMxA(T103A) is an antivirally inactivemutant
of hsMxA. Error bars represent standard deviation
across three biological replicates. HA-tagged MxA
and bactin protein levels were detected in lysates
by Western blot. The phylogenetic relationships
of MxA derived from representative species with-
in hominoid, old world monkey and new world
monkey lineages are indicated by a cladogram.
(B) Differential antiviral activity of human and
AGM MxA orthologs is dependent on loop L4. The
loop L4 (amino acids 556-572) protein sequence
alignment is shown with positively selected sites
that differ between hsMxA and agmMxA in gray
(top). Dose-responsiveness of the antiviral activity
of wild-typeMxA and L4 chimeras was determined
by cotransfecting increasing amounts of MxA ex-
pression constructs with the THOV minireplicon
into 293T cells. MxA antiviral activity is measured
as described in Figure 2A (middle). The Western
blot analysis depicts the expression levels of
the recombinant MxA proteins in the cell lysates
(bottom).
(C) Restriction of THOV infectivity by human and
AGM MxA is contingent on a single amino acid.
Data are presented as percent THOV infected, Mx-
positive cells as measured by immunofluores-
cence for THOV NP and MxA. Error bars represent
standard deviation of three biological replicates.
***p < 0.0001 (t test). See also Figure S2.
(D) Antiviral activity of hsMxA 561 variants. Data are
presented as described in Figure 2A. **p < 0.001
(t test) for values compared to hsMxA(T103A).
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MxA codons (3.7%) have evolved under positive selection, the
signature of positive selection associated with them is quite
strong (average dN/dS ratio of 4.31). These estimates suggest
that althoughmost residues in MxA have evolved under purifying
selection to maintain its structure and enzymatic properties,
positive selection has acted on MxA at discrete residues likely
in response to antagonistic evolution with viruses.
We found no evidence for positively selected sites in the BSE
domain of MxA, and limited evidence in the G and N-terminal
domains (Figures 1B and 1C). Instead, the majority of positively
selected sites were located in the MxA stalk domain, which
has the most significant domain-specific signature of positive
selection. Within the stalk domain by far the most striking enrich-
ment of positively selected sites is in the unstructured loop L4
with 18.6% of codons evolving with an average dN/dS value of
5.08, revealing a dramatic history of positive selection in L4
across primates. The overall signal of positive selection in the
stalk domain is markedly reduced when L4 residues 533-572
are removed from the analysis (Figure 1C). Interestingly, we
observed that there has been an almost complete replacement
of the L4 residues between 559 and 566 (Figure 1B, gray box)
that distinguish hominoid and old world monkey from new world
monkey sequences. However, the new world monkey MxA
divergence is not the only cause of a positive selection signature;600 Cell Host & Microbe 12, 598–604, October 18, 2012 ª2012 Elsevevolutionary analysis of only hominoid and old world monkey
MxA sequences also showed robust evidence of positive selec-
tion inMxA even in this less divergent sequence set (Figure 1C).
These analyses indicate that significant evolutionary pressures
have acted on MxA throughout primate evolution. The cumula-
tive evidence for positive selection in MxA, particularly given
the enrichment of sites in L4, strongly suggests that this
surface-exposed loop, which is disordered in the recently deter-
mined MxA structure (Gao et al., 2011), has been subject to
recurrent and strong positive selection during primate evolution.
Loop L4 Is the Determinant of MxA Antiviral Specificity
against Thogoto Virus
To determine whether the observed positive selection in primate
MxA has functional consequences,MxA coding sequences from
15 representative primate species were subcloned into mam-
malian expression constructs with a N-terminal HA-epitope.
Protein expression was measured by Western blot analysis of
cell lysates from transfected 293T cells, and only minor variation
in protein expression was observed across the 15 orthologs and
hsMxA(T103A), an inactive form carrying a threonine to alanine
mutation in the G domain (Ponten et al., 1997) (Figure 2A). We
then tested the antiviral function of primate MxA orthologs using
the Thogoto virus (THOV) minireplicon system as a readout of
MxA antiviral activity. Previous studies have shown that hsMxAier Inc.
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is sensitive to titration of both hsMxA and NP (Weber et al.,
2000), making it an ideal ‘surrogate’ to test the functional con-
sequences of variation across primate MxA orthologs. In this
assay, the viral polymerase components (PB2, PB1, PA) and
NP are delivered in trans to drive the expression of a firefly lucif-
erase from a viral RNA minigenome in antisense orientation that
is flanked by viral 50 and 30 UTRs. Firefly luciferase expression is
detected 24h-post transfection and normalized to Renilla lucif-
erase levels, serving as a transfection control. Luciferase expres-
sion in the absence of MxA is normalized to 100% polymerase
activity.
We found that hsMxA reduces THOV minireplicon activity
by 50-fold when compared to either the inactive mutant
hsMxA(T103A) or no MxA (Figure 2A). MxA from great apes
reduced THOV primary transcription by 4 to 20-fold. In contrast,
MxA proteins from gibbons, old world monkeys and new world
monkeys were inactive (less than 2-fold reduction). The ob-
served species-specificity indicates that genetic divergence of
primate MxA orthologs bears dramatic functional consequences
for MxA antiviral activity against THOV.
Since there is a marked enrichment of positively selected sites
in L4, we tested whether divergence in L4 might explain differ-
ences in antiviral activity. Therefore, we generated L4 chimeras
between hsMxA (active) and the inactive ortholog from Afri-
can green monkey (agmMxA). Introduction of human L4 into
agmMxA (agmMxA(hsL4)) resulted in a dose-dependent rescue
of activity against the THOV minireplicon (Figure 2B). Likewise,
replacement of hsL4 with that of agmMxA (hsMxA(agmL4)) had
the opposite effect, attenuating the block on THOV transcription.
Thus, the loop L4, which we identified as evolving under positive
selection, is a determinant for the antiviral specificity of MxA.
Next, we tested the hsMxA and agmMxA chimeras in the
context of virus infection. Vero (AGM) cells transfected with
wild-type hsMxA or agmMxA were infected with THOV. We as-
sessed intracellular viral replication by monitoring the accumula-
tion of viral NP via immunofluorescence. In agreement with the
results from the THOV minireplicon, viral infectivity was severely
reduced in the presence of hsMxA and agmMxA(hsL4), but
not agmMxA and hsMxA(agmL4) (Figure 2C). Additionally, the
congruence of antiviral effects seen in the minireplicon assay
in human cells (Figure 2B) and viral infection assay in AGM
cells (Figure 2C) discounts the formal possibility that L4 effects
are due to coevolution with host-specific cofactors that differ
between species. Taken together, our results demonstrate that
the difference in antiviral function between hsMxA and agmMxA
is the result of sequence variation in L4.
A Single Amino Acid Confers MxA Antiviral Specificity
for THOV
HsMxA and agmMxA differ by four amino acids in L4. Of these,
we found that two positions, 561 and 566, are evolving under
recurrent positive selection (Figures 1B and 1C). We focused
on an analysis of position 561 since the serine residue at position
566 is shared between hsMxA and orthologous MxA proteins
inactive against THOV (e.g., Barbary macaque, see Figure S2A).
We mutated the phenylalanine at position 561 in hsMxA to the
valine found in agmMxA, and also introduced the reciprocal
V561F mutation into agmMxA. These single amino acid changesCell Hostcompletely recapitulated the L4 phenotype in both hsMxA and
agmMxA backgrounds in infected cells and in the THOV minire-
plicon system (Figures 2C and S2B). Thus, a single amino acid
evolving under positive selection in L4 largely determines viral
specificity of MxA for THOV.
To understand in greater detail themolecular consequences of
changes at residue 561, we tested amino acids present in homi-
noid and old world monkey species (hsMxA -F561I, -F561L and
-F561V) as well as those that could be sampled by a single bp
mutation of the hsMxA F561 codon (hsMxA -F561C, -F561Y
and -F561S). Only wild-type F561 and F561Y restricted the
THOV minireplicon whereas the other mutations dramatically
reduced the antiviral activity of hsMxA (Figure 2D). Given the
biochemical similarities of phenylalanine and tyrosine, we tested
hsMxA-F561W, which also restricted THOV, albeit to a lesser
degree (Figure 2D). These results reinforce the concept that
MxA antiviral specificity for THOV is conferred by a single amino
acid with specific biochemical requirements.
Functional Conservation of L4
One prediction of the proposed role for L4 in MxA target recog-
nition is that L4-mediated specificity is modular. If that is the
case, the antiviral properties of hsMxA might be transferable to
a more distantly related Mx protein simply by transplanting the
loop L4 of hsMxA. Mouse Mx1 (mmMx1) is relatively inactive
against THOV although it does confer some protection in vivo
(Haller et al., 1995). We made chimeras replacing the loop L4
of mmMx1 with that from hsMxA, mmMx1(hsL4), and compared
it to wild-type mmMx1 in the THOV minireplicon assay. Catalyt-
ically-deficient chimeras were also constructed by mutating the
K49A in the G domain (Pitossi et al., 1993). We found that
mmMx1(hsL4) gained robust activity against THOV (Figure 3A).
We repeated these experiments using THOV infection of trans-
fected Vero cells and again found that mmMx1(hsL4) is signifi-
cantly more potent in blocking THOV than mmMx1 (Figure 3B).
Thus, the loop L4 encodes mmMx1 specificity for THOV, which
strongly argues that L4 is a modular domain that defines MxA
specificity for targeted viral structures.
L4 Influences Binding of MxA to THOV NP
Wepreviously identified the viral NP as the target of MxA antiviral
action (Zimmermann et al., 2011) and demonstrated interaction
of hsMxA with THOV NP by coimmunoprecipitation (Kochs and
Haller, 1999). To test if the gain-of-function of the chimeric pro-
teins is accompanied by L4-mediated binding of THOV NP, we
monitored the association of NP with Flag-tagged Mx proteins
in THOV-infected cells. HsMxA but not mmMx1 associated
with THOV NP, as indicated by coimmunoprecipitation (Fig-
ure 3C). Furthermore, the mmMx1(hsL4) chimera gained the
ability to bind NP (Figure 3C) concomitant with the gain of anti-
viral function. Accordingly, inserting the agmL4 into hsMxA
severely reduced NP association (Figure S3). This indicates
that L4 influences hsMxA interaction with and resultant speci-
ficity for the THOV NP. On the other hand, we did not observe
rescue of NP binding by the reciprocal agmMxA(hsL4) protein
(Figure S3). The discrepancy in NP coimmunoprecipitation by
agmMxA(hsL4) versus mmMx1(hsL4) proteins may be mediated
by presently unidentified residues outside of L4 that differ
between the mmMx1 and agmMxA proteins, which could also& Microbe 12, 598–604, October 18, 2012 ª2012 Elsevier Inc. 601
Figure 3. Loop L4 Is a Functional Module of
MxA Antiviral Activity
(A) Human L4 rescues mouse Mx1 antiviral activity
against the THOV minireplicon. mmMx1 expres-
sion constructs were cotransfected with the THOV
minireplicon system into 293T cells; the experi-
ment was otherwise carried out as in Figure 2B.
mmMx1(hsL4) contains an exchange of mmL4 for
the L4 of hsMxA. mmMx1(K49A) is a GTPase
inactive mutant with no antiviral activity.
(B) Human L4 determines the antiviral activity of
mmMx1 against THOV infection. Percent infec-
tivity was measured as described in Figure 2C.
Error bars represent standard deviation of three
biological replicates. ***p < 0.0001.
(C) L4 mediates the interaction between MxA and
THOV NP. Coimmunoprecipitation of viral NP with
hsMxA and mmMx1 proteins was performed with lysates of THOV-infected (+) or uninfected (-) 293T cells transfected with the indicated Flag-tagged Mx
expression constructs. Immunoprecipitation was performed using anti-Flag-affinity gel and the precipitated proteins were detected byWestern blot with viral NP
and MxA-specific antibodies. The lower panel shows the input of viral NP, MxA and b-tubulin in whole cell lysates. See also Figure S3.
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THOV NP.
MxA Antiviral Specificity for Influenza A Virus Is
Mediated by L4
We recently reported that avian influenza A viruses like contem-
porary H5N1 isolates are sensitive to the antiviral action of
hsMxA (Dittmann et al., 2008; Zimmermann et al., 2011). We
investigated whether the dramatic positive selection of primate
MxA had any consequences on restriction of H5N1 by analyzing
the effect of hsMxA and agmMxA in Vero cells infectedwith avian
influenza strain A/Thailand/1/04. Expression of hsMxA blocked
virus replication by 10-fold (Figure 4); however agmMxA only
had a modest effect on influenza viral replication, when com-
pared to the inactive control hsMxA(delL4). To determine
whether differences in L4 could also account for this disparity,
we tested L4 chimeric proteins for antiviral activity. We found
that adding the L4 region of agmMxA or the single amino acid
exchange F561V to hsMxA decreased its restriction of viral
replication. Conversely, adding the L4 region of hsMxA or only
V561F to agmMxA increased its antiviral activity to the same
level as the wild-type hsMxA protein (Figure 4). Taken together,
these results are consistent with a generalized function for the
loop L4, and F561 in particular, in MxA antiviral specificity for
orthomyxoviruses.
DISCUSSION
The diversity of viruses that MxA restricts is at odds with the
observed specificity in MxA targeting of unique viral structures.
Here, we leverage the antagonistic relationship between MxA
and its targets using an evolution-guided approach to resolve
the biological basis of MxA antiviral specificity. By analyzing
signatures of recurrent positive selection characteristic of arms
races between host and viral genomes, we identified a cluster
of positively selected residues in loop L4 of MxA that predicts
its role for antiviral specificity. Using viruses known to be
susceptible to hsMxA as ‘surrogates’ to reveal functional conse-
quences of ancient diversifying selection in primate MxA L4, we
demonstrate that L4 is indeed a major determinant of primate602 Cell Host & Microbe 12, 598–604, October 18, 2012 ª2012 ElsevMxA antiviral activity against the orthomyxoviruses THOV and
influenza A. Given that single amino acid mutations confer MxA
specificity at a site recurrently altered by positive selection, we
propose that the disordered surface-exposed loop L4 mediates
MxA antiviral specificity. Although it is possible that this speci-
ficity manifests epistatically, the recurrent positive selection
and demonstrated influence of L4 on the MxA - THOV NP inter-
action strongly implicates L4 as a direct interface of MxA target
recognition.
The evolutionary signature of positive selection on MxA L4
suggests a mechanism that explains the conundrum of MxA
target specificity and antiviral breadth. First, single amino acid
changes in the positively selected L4 can have significant con-
sequences for altering MxA antiviral specificity without being
affected by other changes in L4 i.e., F561 worked in the context
of both human and AGM proteins. These experiments suggest
there is relatively little epistasis between different L4 residues.
We propose that other positively selected residues in L4 may
determine specificity to additional viruses similar to the role
that residue 561 plays as a specificity determinant for MxA
against THOV. Thus, adaptation to a newly encountered path-
ogen could occur while not compromising pre-existing substrate
specificity or antiviral range.
Second, although bearing the most striking signature of
positive selection, loop L4 is not the only adaptive surface that
might alter MxA specificity (Figure 1B). For example, great
apes share identical loop L4 sequences yet differ in strength of
antiviral activity suggesting that L4 is not the only domain in
MxA that determines target specificity (Figure 2A). Moreover,
the observation that hsL4 is sufficient for MxA interaction with
THOV NP in the context of mmMx1 but not agmMxA also points
to non-L4 determinants that influence MxA specificity. Other
positively selected sites might represent distinct interaction sur-
faces for different classes of viral pathogens as suggested for
avian Mx genes, which display marked variation in an avian-
specific region in the distal N-terminus of the protein (Berlin
et al., 2008). Thus, independent specificity determinants may
help MxA adapt against a wide variety of viruses. Alternatively,
these sites may function indirectly, for example by optimizing
L4 positioning. Future studies will help elucidate not only theier Inc.
Figure 4. The Loop L4 Mediates Functional Differences in Primate
MxA Antiviral Activity against Influenza A Virus
Restriction of A/Thailand/1/04 infection by hsMxA and agmMxA. Data
are presented as percent of infected, Mx-positive cells as measured by
immunofluorescence for viral NP and MxA. Error bars represent standard
deviation of three biological replicates. ***p < 0.0001 (t test).
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MxA surfaces are used to recognize distinct viral pathogens.
While we expect that further interrogation of diversifying sites
in MxA will shed light on MxA antiviral specificity and mecha-
nisms of restriction, it is also interesting to note that the few
positively selected sites inMxA are in stark contrast to the strong
purifying selection acting on the majority of the MxA protein. An
explanation for the dearth of positive selection in the rest of the
protein is that evolution is limited by a strictly conserved GTPase
architecture. Host-host coevolutionary interactions with cellular
cofactors, such as UAP56 helicase (Wisskirchen et al., 2011),
may further constrain MxA evolution. Therefore, flexibility in sub-
strate recognition may have arisen in L4 to accommodate the
conservation of the rest of the protein. Indeed, the transfer of
hsMxA L4-mediated specificity to rodent Mx1 suggests that
while the L4 function is widely conserved, divergence in L4
encodes unique antiviral specificities that reflect a history of
lineage-specific arms races against ancient pathogenic viruses
in primates.
Recent insights from crystallographic data also help to put our
findings in biochemical context. Although L4 was unresolved in
the hsMxA structure, the resulting structural model situates the
loop L4 facing outward from the inner surface of a ring-shaped
MxA oligomer in which the G domains are at the periphery and
the stalks assemble in the middle in a crisscross pattern (Gao
et al., 2011; von der Malsburg et al., 2011). This configuration
permits extensive, repetitive contacts between the assembled
MxA oligomer and its substrate. The model is particularly
appealing for THOV and other negative-sense RNA viruses,
because the putative viral substrate NP is repetitively bound to
the viral RNA forming a large superhelical structure (Kochs and
Haller, 1999; Reichelt et al., 2004). MxA oligomerization andCell Hostcooperative target bindingmay also explain the large phenotypic
consequences for antiviral activity observed for single amino
acid mutations in L4. Even subtle differences in the binding
affinity between MxA and NP may largely determine antiviral
specificity because their effect is amplified synergistically on
amultimeric target like the viral nucleocapsid (Haller et al., 2010).
How the comparatively diminutive host innate immune reper-
toire withstands the diversity and rapid evolution of pathogens
is a long-standing problem. Taken together, our data provide
insight into the molecular nature of antiviral breadth exhibited
by one effector of innate immunity, MxA, in response to path-
ogen diversity. Our work suggests that breadth may be achieved
through the evolution of specificity domains that lie within evolu-
tionarily dynamic and structurally ‘flexible’ regions of otherwise
conserved antiviral proteins.
EXPERIMENTAL PROCEDURES
Sequencing of Primate MxA Genes
Primate MxA genes were amplified from RNA isolated from cell lines obtained
from Coriell Cell Repositories (Camden, NJ). Gene-specific one-step reverse-
transcription polymerase chain reaction (RT-PCR) was conducted using
SuperScript III One-Step RT-PCR with Platinum Taq (Invitrogen) to produce
complementary DNA (cDNA) using degenerate primers: (F: 50 – CAAAGAAG
GAAGATGGTTSTTTCCGAAGTGG - 30 and R: 50 – TTAACCGGGGAACTGGG
CRAG – 30). cDNA was sequenced and assembled using CodonCode Aligner.
The following sequences were obtained from Ensembl and were not indepen-
dently validated: M. mulatta (rhesus macaque): ENSMMUT00000021494 and
C. jacchus (marmoset): ENSCJAT00000021974.
MxA Sequence Analysis
Sequences were aligned in ClustalX and edited to remove indels. ML tests
were performed with CODEML using the PAML software suite (Yang, 2007),
as previously described (Sawyer et al., 2005). Briefly, sequences were sub-
jected to ML tests using NS sites models disallowing (M7) or allowing (M8)
positive selection. For each comparison themodels allowing positive selection
gave the best fit to the data. The result was consistent under varying models of
codon frequency (F61 and F3x4). The same site-specific analyses also
provided individual amino acids with high posterior probabilities that are
consistent with positive selection.
Plasmids
MxA coding sequence was amplified using AccuPrime Pfx SuperMix (Invitro-
gen) from cDNA derived from indicated primate species and subcloned into
pcDNA3 with an N-terminal hemagglutinin (HA) or Flag epitope. HsMxA and
mmMx1 expression plasmids have been described previously (Zimmermann
et al., 2011). L4 chimeraswere generated by PCR. Pointmutationswere gener-
ated using Quikchange site-directed mutagenesis (Stratagene).
Minireplicon Assay
The THOV minireplicon assay was performed in 293T cells in a 96-well format.
Briefly, 4.0 ng each of PB2, PB1 and PA, 1.0 ng of NP, all in pCAGGS expres-
sion vector, as well as 20 ng pHH21-vNP-FF-Luc (firefly luciferase), 50 ng Tk-
luc (Renilla) (Promega) and varying input or a fixed amount of 200 ngMxA plas-
mids were cotransfected into 293T cells using the reagent TransIT-LT1 (Mirus
Bio). At 24h post-transfection, luciferase activity wasmeasured using theDual-
Glo system (Promega). Expression of MxA proteins was detected by Western
blot analysis usingmouse anti-HA.11monoclonal antibody 16B12 (Sigma) and
rabbit anti-bactin polyclonal antibody AB-8227 (Abcam). Corresponding data
from minireplicon assays and Western blots are derived from samples gener-
ated from a single master mix. All experiments were done in triplicate.
Transfection, Viral Infection and Coimmunoprecipitation
Vero cells were transfected in 24-well plates with 250 ngMxA-expressing plas-
mids and nanofectin (PAA) for 24 hr and then infected with 10 moi of THOV,& Microbe 12, 598–604, October 18, 2012 ª2012 Elsevier Inc. 603
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5 hr. Then, the cells were fixed with 3% paraformaldehyde and MxA and viral
NP expression were detected by immunofluorescence analysis using specific
antibodies as described previously (Dittmann et al., 2008; Haller et al., 1995).
For immunoprecipitation, 293T cells were transfected in six-well plates with
1 mg of Flag-MxA-encoding plasmids for 24 hr and then infected with 10 moi of
THOV for additional 24 hr. Cells were lysed in buffer, 50 mM Tris, pH 8.0,
150 mM NaCl, 1 mM EDTA, 0.5% NP-40. The supernatants were used for
immunoprecipitation of Flag-MxA using Anti-FLAG-M2 affinity gel (Sigma)
for 2 hr at 4C. After washing in lysis buffer the precipitated proteins were
eluted in SDS-sample buffer at 95C for 5 min. Coprecipitated MxA and viral
NP were detected by Western blotting using monoclonal antibodies specific
for MxA and THOV NP (Kochs and Haller, 1999) and b-tubulin (Sigma).
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